OXiGENE (OXGN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oil gains 3% as US-Iran peace talks in stalemate
- Oppenheimer sees AI software winners as focus shifts to ROI
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
OXiGENE Reports Third Quarter 2014 Financial Results
November 12, 2014 4:00 PM EST- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
- Two Phase 2 Fosbretabulin Studies Initiated in Ovarian and Gastrointestinal Neuroendocrine Tumors (GI-NETs) -
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter ended September 30, 2014.
"With a stronger cash balance in place, we have made important progress this quarter in advancing our pipeline of novel... More
